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Abstract: To assess the utility of makorin ring finger protein 1
(MKRN1) as a marker of cervical pathology.
A PROspective specimen collection and retrospective Blinded
Evaluation study was conducted. Liquid-based cytology samples were
collected from 187 women, embedding all residuals as cell blocks for
immunohistochemical staining of MKRN1 and P16 INK4a. Results of
liquid-based cervical cytology, immunostained cell block sections, and
human papillomavirus (HPV) hybrid capture (with real-time polymer-
ase chain reaction) were analyzed. Clinical outcomes were analyzed
overall and in subsets of specimens yielding atypical squamous cells of
undetermined significance or low-grade squamous intraepithelial
lesions.
Makorin ring finger protein 1 positivity and grades (1–3) of cervical
intraepithelial neoplasia (CIN) increased in tandem (CIN1, 32.4%;
CIN2, 60.0%; and CIN3, 80.0%), reaching 92.3% in invasive cancer.
Sensitivity, specificity, positive predictive value, and negative predic-
tive value in detecting CIN2þ via MKRN1 were 73.8%, 76.8%, 75.6%,
and 75.0%, respectively. The performance of liquid-based cytology was
poorer by comparison (61.3%, 69.5%, 66.2%, and 64.8%, respectively),
and HPV assay (versus MKRN1 immunohistochemical staining) dis-
played lower specificity (67.7%). Combined HPVþMKRN1 testing
proved highest in sensitivity, specificity, positive predictive value, and
negative predictive value (71.8%, 85.5%, 82.3%, and 76.5%, respect-
ively), whereas corresponding values for cytologyþHPV (60.6%,
81.8%, 75.4%, and 69.2%) and cytologyþMKRN1 (58.8%, 84.1%,MD, PhD, Doo By , PhD,
Jae-Hoon Kim, MD, PhD
measures (100%, 72.7%, 73.9%, and 100%), followed by cytolo-
gyþMKRN1 (100%, 50.0%, 60.7%, and 100%).
Makorin ring finger protein 1 displayed greater sensitivity and
specificity than liquid-based cytology and proved more specific than
HPV assay. In combination testing, MKRN1þHPV showed the highest
sensitivity and specificity levels. The MKRN1 biomarker may be a
useful adjunct in primary cervical cytology screening.
(Medicine 95(3):e2425)
Abbreviations: AGUS = atypical glandular cells of undetermined
significance, ASCUS = atypical squamous cells of undetermined
significance, CIN = cervical intraepithelial neoplasia, CIS =
cervical carcinoma in situ, FADD = Fas-associated protein with
death domain, HC2 = Hybrid Capture 2, HPV = human
papillomavirus, HSIL = high-grade squamous intraepithelial
lesion, IHC = immunohistochemical, LSIL = low-grade
squamous intraepithelial lesion, MKRN1 = makorin ring finger
protein 1, NPV = negative predictive value, PPV = positive
predictive value, PROBE = PROspective specimen collection and
retrospective Blinded Evaluation.
INTRODUCTION
R egimented cytologic screening has contributed significantlyto reducing the incidence of cervical cancer,1 but as the sole
means of testing, its low diagnostic accuracy (owing to limited
reproducibility in cervical intraepithelial neoplasia [CIN] detec-
tion) is problematic.2 Consequently, novel molecular assays
have emerged to augment this conventional approach.3
Given that human papilloma virus (HPV) infection is
implicated in cervical carcinogenesis, a recent study has found
HPV deoxyribonucleic acid (DNA) testing more sensitive than
cervical cytology, detecting high-grade CIN earlier4 and thus
furthering efforts to prevent invasive cancer. Unfortunately,
HPV screening has low specificity in this setting. Although such
infections are common and are apt to resolve naturally within 1
to 2 years, both transient bouts and persistent infections
(accounting for high-grade CIN)4 yield positive test results.
Many researchers are now focused on developing more
effective screening tests for CIN detection, hoping to improve
the specificity of cytologic preparations and HPV tests while
maintaining the generally high respective sensitivities. Bio-
markers of HPV-related genes strongly expressed in carcino-
genesis are of particular interest. Prime examples include Ki-67
(involved in cellular proliferation) and p16INK4a (a cell-cycle
regulatory protein), both of which have been identified in prior
studies as markers of CIN.4–8 Conversely, p16INK4a immunor-
eactivity is also observed in endocervical or metaplastic cells
and in benign atrophic cells, requiring attention to cellrpreting stained specimens.9
er protein 1 (MKRN1) is a transcriptional
ase, and a negative regulator of tumor
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suppressor genes p53 and p21. It has been noted that a reduction
in MKRN1 induces growth arrest by activating p53 and p21.10
Makorin ring finger protein 1 also blocks cancer cell death by
inducing ubiquitination and thus promoting degradation of Fas-
associated protein with death domain, a key element in death
receptor-activated extrinsic apoptosis. BecauseMKRN1andFas-
associated protein with death domain participate in necrosome
formation and necroptosis regulation, downregulation of
MKRN1 understandably has been shown to have a major inhibi-
tory effect on tumor enlargement in breast cancer. Furthermore,
MKRN1 messenger ribonucleic acid levels are significantly
higher in cancerous than in normal cervical tissue.11
The current study was conducted to determine if MKRN1
immunohistochemical (IHC) staining is a viable adjunct in
diagnosing cervical cancer or its precursor lesions. Specifically,
4 diagnostic procedures (cytology, HPV assay, MKRN1, and
p16INK4a immunostaining) were evaluated in terms of sensi-
tivity, specificity, positive predictive value (PPV), negative
predictive value (NPV), and accuracy in diagnosing CIN2þ.
For this purpose, residual liquid-based cytology samples
enabled immunostaining of MKRN1 and p16INK4a biomarkers.
METHODS
Study Population
Specimens were prospectively collected between July,
2013 and February, 2014, following approval by the Institu-
tional Review Board for Clinical Research at Gangnam Sever-
ance Hospital. The study population (n¼ 189) consisted of
women 18 years old who were referred to the above facility
for abnormal cervical cytology results; who were admitted with
benign conditions (eg, uterine fibroids or adenomyosis) for
hysterectomies; or who visited the hospital for regular checkups
and routine cervical cytology screening. Each enrolee was
subjected to cervical cytology screening, HPV assay, and
immunostaining for MKRN1 and p16INK4a markers (per pro-
tocol). Exclusions were as follows: age <18 years, prior hys-
terectomy, previous cancer of noncervical origin, treatment for
CIN or invasive cancer within last 5 years, chronic illness with
immunocompromise, or refusal to consent/participate. The
clinical performance of each test method was determined retro-
spectively, based on histologic findings in punch biopsy or
hysterectomy specimens.
Liquid-based Cervical Cytology
A liquid-based cervical cytology sample was obtained
from each patient via Cytobrush device (ThinPrep 2000 system,
Cytyc Corp, Boxborough, MA). Two pathology specialists
(same institution affiliates) rendered all diagnoses, based on
the Bethesda system (2001). In the event of conflicting results
(primary care records versus referral hospital), higher grade
lesions prevailed for analysis.
Human Papillomavirus Testing
The Hybrid Capture 2 (HC2) assay (Digene Corp, Gaithers-
burg,MD),which is designed to detect 13 types of high-riskHPV,
was routinely performed. Results were expressed as a ratio
between light emitted from a test specimen and from 1pg/mL
HPV DNA (average of 3 control specimens). For example, 1
relative light unit would correspond with 1 pg/mLHPVDNA in a
Lee et alspecimen tested.BecauseHC2 assays cannot distinguish between
single and multiple infections, nor distinguish between HPV
types 16 and 18, the cobas 4800 HPV test (Roche, Pleasanton,
2 | www.md-journal.comCA) was also performed. Results were reported as negative, type
16 or 18, and other types. Positive HPV testing was equated with
HPVpositivity byHC2 assay or detection of anyHPV type (HPV
16 or 18 and others).
Histology
Punch biopsies were obtained by a specialist in colposcopy
to confirm normal cytology results or corroborate the presence
of high-risk HPV infection. Patients with CIN1 or lower grades
were followed without further treatment. In every patient with
CIN3þ and in most with CIN2, either a loop electrosurgical
excision procedure or a hysterectomy was done. Those diag-
nosed with invasive cervical cancer underwent radical hyster-
ectomy. If punch biopsy and loop electrosurgical excision
procedure or hysterectomy specimens resulted in conflicting
diagnoses, the highest grade prevailed for analysis.
Cell Block Preparation
Cell blocks for immunostaining of MKRN1 and p16INK4a
were prepared from residual samples (ThinPrep Pap Test,
Hologic Inc, Marlborough, MA), based on a method described
in a number of previous studies. Specifically, residual Preserv-
Cyt Solution (Cytyc) was centrifuged (1500 rpm, 5 minutes),
discarding the supernatant and resuspending the pellet in 5 to 8
drops of plasma. Next, 2% calcium chloride was added, mixed
well, and left to coagulate (20 minutes). The resultant clot was
wrapped in lens paper, placed in a tissue cassette, and fixed (10
minutes) in 10% neutral buffered formalin. Completed prep-
arations were sectioned at 4.0mm and stained with hematoxylin
and eosin. Cellular morphology and degree of preservation
were assessed.
Makorin Ring Finger Protein 1
Immunohistochemical Staining
To determine MKRN1 expression, prepared cell blocks
were again sectioned at 400mm, and IHC staining was per-
formed using rabbit anti-MKRN1 antibody and affinity purified
makorin-1 antibody (Bethyl Laboratories Inc, Montgomery,
TX). The UltraVision LP Detection System kit (Thermo Fisher
Scientific, Fremont, CA) was used for indirect staining, using a
biotin-linked secondary antibody labelled with horseradish
peroxidase. The peroxidase reacts with 3,30-diaminobenzidine
tetrahydrochloride, catalyzing a color change, and the slides are
counterstained with hematoxylin. Sections were interpreted by a
pathology specialist, equating a positive result with visible
nuclear staining (Figure 1).
P16INK4a Immunohistochemistry
Expression of p16INK4a in cell block sections was deter-
mined using a p16INK4a-specific monoclonal antibody (Clone
E6H4, Santa Cruz Biotechnology Inc, Dallas, TX) and CINtec
p16-INK4a Cytology kit (Dako Cytomation [now Dako A/S],
Glostrup, Denmark). The slides were then incubated (30 min-
utes) with secondary goat anti-mouse antibody (Dako), fol-
lowed by 3,30-diaminobenzidine tetrahydrochloride (Dako)
incubation (10 minutes) and finally counterstaining with
Mayer hematoxylin.
Statistical Analysis
Medicine  Volume 95, Number 3, January 2016In diagnosing CIN2þ, sensitivity, specificity, PPV, and
NPV were calculated for each test method (cytology, HPV test,
and IHC staining of MKRN1 and p16INK4a) using standard
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
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calculated sensitivity and specificity values, diagnostic
accuracy of each method was determined from receiver operat-
ing characteristic curves. Identical analyses were performed for
each 2-method combination tested in the entire cohort and in
patient subsets showing atypical squamous cells of undeter-
mined significance (ASCUS) or low-grade squamous intrae-
pithelial lesions (LSIL). Each result was expressed as mean,




Results of cytology and histologic examinations are shown
in Table 1. Of the 189 patients originally enrolled for study, 187
remained for the final analysis (excluding 2 for failure to
procure cervical cells). Ultimately, 47 (25.1%) normal and
140 (74.9%) abnormal cytology results were recorded. In the
abnormal subset, histologic examination confirmed 8 (17%)
FIGURE 1. Immunohistochemical staining of makorin ring finger p
high-grade cervical intraepithelial neoplasia (B).with CIN1, 3 (6.4%) with CIN2, 3 (6.4%) with CIN3/cervical
carcinoma in situ (CIS), and 1 (2.1%) with invasive cancer. In
patients (n¼ 140) with abnormal cytology results, ASCUS or








Negative 47 32 (68.1) 8 (17
ASCUS or AGUS 22 5 (22.7) 5 (22
LSIL 55 17 (30.9) 20 (36
ASC-H/HSIL 57 2 (3.5) 5 (8.
Cancer 6 0 0
AGUS¼ atypical glandular cells of undetermined significance, ASC-H
ASCUS¼ atypical squamous cells of undetermined significance, CIN¼
HSIL¼ high-grade squamous intraepithelial lesion, LSIL¼ low-grade squa
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.atypical glandular cells of undetermined significance were
evident in 22, including 5 (22.7%) with negative histologic
presentations, 4 (18.2%) occurrences of CIN2, 6 (27.3%)
instances of CIN3/CIS, and 2 patients (9.1%) with invasive
cancer. In patients (n¼ 55) with LSIL, histologic examinations
were normal in 17, whereas 20 (36.4%) were diagnosed as
CIN1, 12 (21.8%) as CIN2, and 6 (10.9%) as CIN3/CIS. In
patients (n¼ 57) demonstrating atypical squamous cells on
cytology (high-grade squamous intraepithelial lesion/high-
grade squamous intraepithelial lesion not excluded), CIN1
was evident histologically in 5 (8.8%), CIN2 in 13 (22.8%),
and CIN3/CIS in 31 (54.4%), whereas 6 (10.5%) showed
invasive cancer. In patients (n¼ 6) diagnosed with cancer by
cytology, CIN3/CIS was documented in 1 (16.7%), and 5
(83.3%) showed invasive cancer.
Test Performances Versus Histology
Performance levels of the 4 cervical cancer screening tests
under investigation are shown by histologic diagnoses in
Table 2. Findings of reactive cellular change or chronic non-
in in representative sections of normal cervical epithelium (A) andspecific inflammation on cytology were considered negative,
with ASCUS or higher grades of CIN qualifying as positive











.0) 3 (6.4) 3 (6.4) 1 (2.1)
.7) 4 (18.2) 6 (27.3) 2 (9.1)
.4) 12 (21.8) 6 (10.9) 0
8) 13 (22.8) 31 (54.45) 6 (10.5)
0 1 (16.7) 5 (83.3)
¼ atypical squamous cells-high-grade squamous intraepithelial lesion,
cervical intraepithelial neoplasia, CIS¼ cervical carcinoma in situ,
mous intraepithelial lesion.
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Negative 56 12 (21.4) 21 (37.5) 24 (42.9) 10 (17.9) 2 5 3
CIN1 38 12 (31.6) 23 (60.5) 30 (98.9) 33 (86.8) 5 17 11
CIN2 32 20 (62.5) 21 (65.6) 29 (90.6) 29 (90.6) 12 13 4
CIN3/CIS 47 35 (74.5) 36 (76.6) 44 (93.6) 46 (97.9) 17 20 9
Cancer 14 13 (92.9) 12 (85.7) 13 (92.9) 13 (92.9) 9 2 2
, CI
Lee et al Medicine  Volume 95, Number 3, January 2016including 24 (42.9%) who initially appeared positive on
cytology and 21 (37.5%) who tested positive for the p16INK4a
marker. Patient totals in those testing positive by HPV assay and
MKRN1 immunostaining were 10 (17.9%) and 12 (21.4%),
respectively. Of 38 patients with CIN1, 30 showed positivity by
cytology, HPV assay, and p16INK4a immunostaining, whereas
12 tested positive for MKRN1. Of 32 patients (17.1%) diag-
nosed with CIN2, 29 (90.6%), were positive by cytology and
HPV assay, with similar rates for MKRN1 and p16INK4a (20/32
[62.5%] and 21 [65.6%], respectively). In 47 patients (25.1%)
with CIN3/CIS, positive results were recorded as follows:
cytology, 44 (93.6%); HPV assay, 46 (97.9%); MKRN1, 35
(74.5%); and p16INK4a, 36 (76.6%). In 14 patients (7.5%) with
invasive cancer, positivity totals for cytology, HPV test, and
MKRN1 marker were the same at 13 (92.9%), with 12 (85.7%)
positive results for p16INK4a.
Performance of Clinical Test Methods in
Detecting Cervical Intraepithelial Neoplasia 2R
The goal of this study was to accurately diagnose pre-
cancerous cervical pathology. To determine the diagnostic
CIN¼ cervical intraepithelial neoplasia, HPV¼ human papillomavirusaccuracy of the 4 screening tests, we calculated sensitivity,
specificity, PPV, NPV, and diagnostic accuracy for both indi-
vidual tests and 2-method combinations (Table 3). Based on
TABLE 3. Performances of Conventional Cytology, Human Papillo
and p16INK4a) Immunostains in Detecting Cervical Intraepithelial
Sensitivity Specificity
Cytology 92.5 (87.1–97.8) 42.6 (32.6–52.5)
HPV 94.6 (90.0–99.2) 54.3 (44.2–64.3)
MKRN1 73.1 (64.1–82.1) 74.5 (65.7–83.3)
p16 74.2 (65.3–83.1) 53.2 (43.1–63.3)
CytologyþHPV 90.3 (84.3–96.3) 66.0 (56.4–75.5)
CytologyþMKRN1 71.0 (61.7–80.2) 77.7 (69.2–86.1)
Cytologyþ p16 73.1 (64.1–82.1) 69.1 (59.8–78.5)
HPVþMKRN1 68.8 (59.4–78.2) 87.2 (80.5–94.0)
HPVþ p16 71.0 (61.7–80.2) 77.7 (69.2–86.1)
MKRN1þ p16 62.4 (52.5–72.2) 80.9 (72.9–88.8)
HPV¼ human papillomavirus, MKRN1¼makorin ring finger protein 1,
4 | www.md-journal.comhistology, CIN2þ constituted disease positivity. Identical
analyses were conducted for subgroups of patients showing
ASCUS or LSIL on cytology (Table 4). In terms of individual
tests, the HPV assay displayed the highest sensitivity rate
(94.6%), but its specificity was low (54.3%). Liquid-based
cytology, the current primary screening method, showed sen-
sitivity (92.5%) similar to HPV assay, but had the lowest
specificity (42.6%) of the 4 test methods. Makorin ring finger
protein 1 immunostaining proved less sensitive than cytology
(73.1% versus 92.5%) but more specific than HPV assay (74.5%
versus 54.3%). Compared with the MKRN1 marker, immunos-
taining of P16INK4a proved similar in sensitivity (74.2% versus
73.1%) but lower in specificity (53.2% versus 74.5%). Used in
combination, cytology and HPV assay (cytologyþHPV)
showed the highest sensitivity (90.3%) but the lowest specificity
(66.0%) of all combinations studied. Combined use of HPV
assay and MKRN1 immunostaining (HPVþMKRN1) showed
the highest specificity (87.2%). Equivalent sensitivity (71.0%)
and specificity (77.7%), however, were observed for cytology
and MKRN1 marker (cytologyþMKRN1) or HPV assay and
p16INK4a marker (HPVþ p16INK4a) in combination. The second
lowest specificity (69.1%) was encountered with cytology and
S¼ cervical carcinoma in situ, MKRN1¼makorin ring finger protein 1.p16INK4a marker (cytologyþ p16INK4a) in combination, with
cytologyþHPV showing the lowest specificity. Combined
marker screening (MKRN1þ p16INK4a) had the second highest
mavirus Assay, and Biomarker (Makorin Ring Finger Protein 1
Neoplasia 2þ Overall (All Subjects)
All Subjects
PPV NPV Diagnostic Accuracy
61.4 (53.4–69.5) 85.1 (74.9–95.3) 67.4 (60.2–74.0)
67.2 (59.1–75.2) 91.1 (83.6–98.5) 74.3 (67.5–80.4)
73.9 (64.9–82.9) 73.7 (64.8–82.5) 73.8 (66.9–79.9)
61.1 (52.1–70.1) 67.6 (56.9–78.2) 63.6 (56.3–70.5)
72.4 (64.3–80.5) 87.3 (79.6–95.1) 78.1 (71.5–83.8)
75.9 (66.9–84.9) 73.0 (64.3–81.7) 74.3 (67.5–80.4)
70.1 (61.0–79.2) 72.2 (63.0–81.5) 71.1 (64.1–77.5)
84.2 (76.0–92.4) 73.9 (65.7–82.0) 78.1 (71.5–83.8)
75.9 (66.9–84.9) 73.0 (65.7–82.0) 74.3 (71.5–83.8)
76.3 (66.8–85.9) 68.5 (59.8–77.1) 71.7 (64.6–78.0)
NPV¼ negative predictive value, PPV¼ positive predictive value.
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TABLE 4. Performances of Conventional Cytology, Human Papillomavirus Assay, and Biomarker (Makorin Ring Finger Protein 1
and p16INK4a) Immunostains in Detecting Cervical Intraepithelial Neoplasia 2þWithin Atypical Squamous Cells of Undetermined
Significance /Low-grade Squamous Intraepithelial Lesion Patient Subsets
ASCUS/LSIL
Sensitivity Specificity PPV NPV Diagnostic Accuracy
Cytology 100 NA 39.0 (28.1–49.9) 100 39.7 (28.8–51.5)
HPV 100 41.7 (27.7–55.6) 51.7 (38.9–64.6) 100 64.1 (52.4–74.7)
MKRN1 60.0 (42.7–77.5) 62.5 (48.8–76.2) 50.0 (33.7–66.3) 71.4 (57.8–85.1) 61.5 (49.8–72.3)
p16 63.3 (46.1–80.6) 47.9 (33.8–62.0) 43.2 (28.5–57.8) 67.6 (51.9–83.4) 53.9 (42.2–65.2)
CytologyþHPV 100 41.7 (27.7–55.6) 51.7 (38.9–64.6) 100 64.1 (52.4–74.7)
CytologyþMKRN1 60.0 (42.5–77.5) 62.5 (48.8–76.2) 50.0 (33.7–66.3) 71.4 (57.8–85.1) 61.5 (49.8–72.3)
Cytologyþ p16 66.7 (49.8–83.5) 45.8 (31.7–59.9) 43.5 (29.2–57.8) 68.8 (52.7–84.8) 53.9 (42.2–65.2)
HPVþMKRN1 60.0 (42.5–77.5) 81.3 (70.2–92.3) 66.7 (48.9–84.4) 76.5 (64.8–88.1) 73.1 (61.8–82.5)
HPVþ p16 63.3 (46.1–80.6) 72.9 (60.3–85.5) 59.4 (42.4–76.4) 76.1 (63.8–88.4) 69.2 (57.8–79.2)
MKRN1þ p16 43.3 (25.6–61.1) 70.8 (58.0–83.7) 48.1 (29.3–67.0) 66.7 (53.7–79.6) 60.3 (48.5–71.2)
CIN
ring
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method combination with the highest specificity was
HPVþMKRN1. In terms of diagnostic accuracy, HPV assay
and MKRN1 immunostaining were the most accurate methods
in single use (74.3% and 73.8%, respectively), whereas 2-
method accuracy was highest (78.1%) for cytologyþHPV
and HPVþMKRN1.
In patients with ASCUS or LSIL patients, cytology and
HPV assay again showed the highest individual sensitivity
(100%), with low specificity. Sensitivities of MKRN1 and
p16INK4a markers were similar (60.0% and 63.3%, respect-
ively), but MKRN1 showed the highest specificity (62.5%).
In combination, cytologyþHPV earned the highest sensitivity
(100%) but the lowest specificity (41.7%), whereas
HPVþMKRN1 showed high specificity at 81.3%. As individ-
ual tests, HPV assay and MKRN1 immunostaining were the
most accurate (64.1% and 61.5%, respectively), as with patients
overall, whereas cytology was least accurate (39.7%). Of the 2-
method combinations analyzed, HPVþMKRN1 showed the
highest diagnostic accuracy (73.1%), surpassing that of cyto-
logyþHPV (64.1%).
DISCUSSION
To compensate for the low specificities of cytology and
HPV testing, researchers have focused on p16INK4a as a novel
marker for cervical neoplasia. In a large-scale randomized trial,
targeting of p16INK4a reportedly increased diagnostic specificity
and correlated strongly with histologic results.7 Assessment of
p16INK4a overexpression (via immunostaining) and HPV assay
in combination yielded better diagnostic accuracy than conven-
tional cervical cytology and HPV testing. Consequently, the
pursuit of useful adjuncts to existing methods is still a high
priority in ongoing research. In a study conducted by Lee et al11,
overexpression of the MKRN1 protein correlated with cervical
cancer in vivo. Another previous study has also shown that
MKRN1 expression levels in cervical tissue are proportional to
tumor stage or grade of tumor, correlating positively with pAKT
and negatively with phosphatase and tensin homolog (PTEN)
ASCUS¼ atypical squamous cells of undetermined significance,
LSIL¼ low-grade squamous intraepithelial lesion, MKRN1¼makorinexpression levels.12
Outcomes of the current study indicate that HPV and
MKRN1 determinations are similar in terms of diagnostic
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.accuracy (74%), each surpassing cervical cytology (67.4%).
In dual applications (cytologyþHPV and HPVþMKRN1), the
diagnostic accuracies, however, were comparable (78.1%) while
specificities differed. The combination of cytologyþHPV had
the lowest specificity, but individual sensitivities were highest
(92.5% and 94.6%, respectively). Thus, the MKRN1 marker
essentially complements the low-specificity, high-sensitivity
nature of HPV assay, raising overall specificity from 54.3% to
87.2% and delivering the highest diagnostic accuracy. Hence, the
benefit conferred justifies the effort and cost of an added test.
The most difficult scenarios in cervical cancer screening
are those complicated by ASCUS and LSIL. Previous studies
contend that such changes will likely disappear7; therefore,
unnecessary procedures may be avoided by conservative
measures (ie, follow-up observation only). Nonetheless, it is
alarming that a high percentage of patients (55/77, 71.4%) in
our cohort with these cytologic abnormalities eventually were
diagnosed as CIN1þ, and CIN2þ was confirmed histologically
in 30 (39.0%) of these patients. This suggests a clear propensity
for later development of invasive cancer, making it imperative
to separate those who require active intervention from others for
whom observation is sufficient. As such, we investigated the
clinical performance of screening tests in patient subsets show-
ing ASCUS or LSIL on cytology. Outcomes were similar to
those observed in patients overall. In combined HPVþMKRN1
testing, specificity was nearly 2-fold that of cytologyþHPV
(81.3% versus 41.7%), resulting in the highest diagnostic
accuracy (76.5%).
According to epidemiologic studies of HPV, infection rates
are higher in sexually active women <35 years of age, although
most episodes resolve naturally.13 Because younger women
typically have plans of future childbirth, the increased likelihood
of procedure-related obstetric morbidity, such as preterm birth or
incompetent internal os, may become important.14 Moreover,
cytology results indicative of ASCUS, LSIL, or HPV infection
are a potential source of psychologic stress in women. Therefore,
a physician’s decision to opt for follow-up observation (with
patient reassurance) or halt progression to invasive cancer
¼ cervical intraepithelial neoplasia, HPV¼ human papillomavirus,
finger protein 1.through aggressive testing and treatment is critical. The excep-
tional specificity of HPVþMKRN1 in patients of questionable
status (ASCUS or LSIL) is particularly noteworthy.
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Human papillomavirus vaccination coverage has increased
significantly after approximately 8 years of usage for cervical
cancer. The US Food and Drug Administration granted approval
of Gardasil(Merck & Co., Inc., Whitehouse Station, NJ USA) in
2006 and Cervarix(GlaxoSmithKline Biologicals, Rixensart,
Belgium) in 2009.15 As the proportion of patients with invasive
cancer or rapidly progressive high-grade CIN (transitioning to
invasive cancer) declines, owing to effective curtailment of
HPV 16 and 18 serotypes, a commensurate decline in the PPV
of cytology is expected. Thus, the preferred test for primary
cervical cancer screening is gradually shifting from cytology to
the HPV DNA assay, despite the low specificity. Makorin ring
finger protein 1 may then play a key adjunctive role in cervical
screening, as demonstrated herein.
Cytology screening relies on subjective assessments that
prove disproportionately unsatisfactory in less skilled hands.
Trained professionals must carefully search for atypical cells,
which may be obscured by a dearth of normal epithelial
elements. Moreover, intra- or interobserver discrepancies are
possible in interpreting ASCUS and high-grade squamous
intraepithelial lesion. A systematic review of 62 studies con-
ducted by Fahey et al16 to determine the accuracy of the Pap
tests showed wide variations in sensitivity (11%–99%) and
specificity (14%–97%). In contrast, HPV assay is an objective
and highly sensitive automated procedure, with limited oppor-
tunity for medicolegal claims because of disputed results.
The current study is the first to report the features and
benefits of MKRN1 as a diagnostic marker for invasive cervi-
cal cancer/CIN. This study was free of selection bias, given
prospective collection of specimens and treatment guidelines
developed after the study was planned. All data were analyzed
retrospectively, based on histology reports. Makorin ring fin-
ger protein 1 IHC staining was found to be an effective test
method that complemented the low specificity of cytology and
HPV assay. Residual specimens from liquid-based cytology or
cobas HPV analysis may be used for staining, without the
added effort, discomfort, or anxiety during gynecologic exam-
inations. Of particular importance, this method may curb
unnecessary colposcopically directed biopsy and referral rates,
thereby reducing medical costs while safely extending
screening intervals.
In terms of future study considerations, the relationship
between clinical performance of HPVþMKRN1 and patient
age should be investigated, assessing study population subsets.
In addition, polymerase chain reaction-based experiments are
needed to confirm the possibility of more convenient method.
Above all, cost-effective analysis is required to clarify the best
screening strategy including MKRN1 IHC method for diagnos-
ing CIN2þ. Follow-up analysis of whether MKRN1 presence or
absence impacts progression to high-grade CIN is another
important issue.
CONCLUSIONS
In conclusion, comparative clinical performances of
MKRN1 IHC staining and currently available cervical cancer
screening tests indicate that HPVþMKRN1 is the ideal test
combination, despite equivalent accuracy of cytologyþHPV.
The MKRN1 and HPV methods complement 1 another, con-
Lee et alsidering the high sensitivity of HPV assay and the high speci-
ficity of the MKRN1 biomarker. Furthermore, the
HPVþMKRN1 combination was most accurate for diagnosing
6 | www.md-journal.comCIN2þ in ASCUS/LSIL patient subsets. We anticipate that
MKRN1 IHC staining will ultimately emerge as a useful adjunct
to routine cervical cancer screening.
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